Boston Scientific’s (NYSE: BSX) Rhythm Management & Neuro segment accounts for around 30% of the company’s value, according to our estimates. The company restructured its segments in Q1, and Rhythm Management & Neuro segment now also includes Neuromodulation, which has seen double digit growth in the recent years. We have created an interactive dashboard highlighting the company’s Rhythm Management & Neuro segment. It should also be noted that Boston Scientific’s Rhythm Management is facing stiff competition from other players, especially Abbott. Also, regulatory investigations by the U.S. Department of Justice have laid down stricter eligibility requirements for the use of Cardiac Rhythm Management devices.
Source: Forbes May 16, 2018 16:18 UTC